RedHill planning NDA for H. pylori antibiotic following second Phase III readout

By Brian Moy | Dec 3, 2018 | 4:11 PM GMT

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) plans to submit an NDA to FDA next half for Talicia (RHB-105) as first-line treatment